IRIX

IRIDEX ($IRIX) Executives Buy Over 75,000 Shares Amid Stock Plunge; CFO Makes Nearly Daily Purchases

05/16/2025 17:45

Key executives of ophthalmic medical device manufacturer IRIDEX Corporation ($IRIX) have been aggressively purchasing shares over the past few weeks, drawing investor attention. The insiders of this small-cap company stepped in with substantial purchases as the stock price approached the $1 level. Over a three-week period from April 21 to May 15, 2025, IRIDEX's Chief Financial Officer Romeo Dizon, President Patrick Mercer, and Director William Moore collectively acquired more than 75,000 shares for approximately $86,000. Notably, Director William Moore made the largest individual commitment, purchasing about 57,500 shares through five separate transactions during this period. His purchases were made through the William M. Moore Trust and the Patricia A. Moore Trust. Equally significant is CFO Romeo Dizon's consistent pattern of almost daily small purchases. Between April 21 and May 14, he executed 11 separate transactions totaling about 10,665 shares. The company's President, Patrick Mercer, also participated with two purchases on April 24 and 28, acquiring a total of 7,546 shares. These insider purchases continued even after IRIDEX announced its first quarter 2025 results on May 13. The company reported $11.9 million in revenue and a net loss of $1.7 million for Q1. This represents a year-over-year revenue increase of 1.10%, while significantly reducing net losses from $3.5 million in the same period last year. Additionally, the company's gross profit reached $5.1 million with a margin of 42.5%, up from 37.9% in the prior year period. The company's stock has declined approximately 61% over the past year, with particularly steep drops in early 2025. After trading at $1.83 in early January, the stock fell to as low as $0.80 in mid-March before recovering slightly to current levels around $1.00. Against this backdrop of share price deterioration, the concentrated insider buying suggests management believes the current stock price significantly undervalues the company's intrinsic worth. IRIDEX is a medical technology company specializing in laser systems and instruments for ophthalmology, particularly for treating glaucoma and retinal disorders. Recently, the company has been focusing on strategic investments to enhance growth and stabilize its financial position. Notably, IRIDEX secured a strategic investment of $10 million, with an option for an additional $10 million to support future growth initiatives. The company's flagship Cyclo G6® product family continues to be a significant revenue driver, with sales increasing by 8% year-over-year to $3.2 million. However, the retina product segment faced challenges, with revenue decreasing to $6.6 million from $6.8 million. Management has expressed optimism about achieving EBITDA breakeven in upcoming quarters due to ongoing cost-cutting measures and strategic reviews. IRIDEX currently has a market capitalization of approximately $17 million, with a price-to-sales ratio of just 0.34. The company holds $7.24 million in cash, with a current ratio of 1.95 indicating good short-term liquidity. Its debt-to-equity ratio stands at 77.34%, suggesting a moderate level of leverage. While insider buying is never a guarantee of stock appreciation, the 'cluster buying' pattern where multiple senior executives purchase shares simultaneously is generally interpreted as a positive signal. The CFO's consistent almost daily purchases in particular may indicate strong confidence in the company's financial trajectory. Investors should note that the company is still operating at a loss, but the profitability improvements in the first quarter results combined with the strong buying signals from executives suggest the possibility of positive change. The upcoming quarterly results, effects of cost-cutting measures, and growth momentum in the Cyclo G6® product line could serve as important catalysts for a potential stock recovery.

You can receive notifications when news is published.